Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men.

Je Hyun SeoJung-Min KohHan Jin ChoHanjun KimYoung-Sun LeeSu Jung KimPil Whan YoonWon KimSung Jin BaeHong-Kyu KimHyun Ju YooSeung Hun Lee

Published in: Journal of cachexia, sarcopenia and muscle (2024)

SM (16:0), reflecting low muscle strength, and CER (24:1) and SM (16:0), reflecting low muscle mass, are potential circulating biomarkers for sarcopenia in men. Further research on sphingolipid metabolites is required to confirm these results and provide additional insights into the metabolomic changes relevant to the pathogenesis and diagnosis of sarcopenia.

Keyphrases

skeletal muscle
ms ms
community dwelling
middle aged
human health
risk assessment
climate change